{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:41:21Z","timestamp":1784263281520,"version":"3.55.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for osteoarthritis (OA), despite various adverse effects (AEs). Previous studies were often limited by small sample sizes, a focus on only predefined outcomes, and an imbalanced research coverage across NSAID subtypes. These factors can cause confirmation or heterogeneity bias, and in clinical practice, focusing on only well-known AEs may lead to the overlooking of other potential AEs. To address this, we conducted a hypothesis-free screening of AEs within a large, single cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using a nationwide South Korean cohort, we selected 888,909 newly diagnosed OA patients with health screening data between 2010 and 2014. The first three characters of ICD codes were considered as potential AEs and their effects were evaluated. To reduce reverse-causation bias, we first used chi-square and Poisson tests to identify significant indications, and excluded the corresponding ICD codes. Time-dependent survival analysis was conducted, defining NSAID users as patients with any annual medication possession ratio (MPR) \u2265 0.1. Additionally, a self-controlled case series analysis was conducted, defining the risk period as up to 6\u00a0months after NSAID intake. Further, we assessed the association between five NSAID subtypes (aceclofenac, meloxicam, loxoprofen, celecoxib, and naproxen) and AEs, and compared their adjusted hazard ratios (aHRs) with each other.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We confirmed previously reported AEs (e.g., anemia, cerebrovascular and cardiorenal diseases). The risk of nephrotoxicity varied significantly by NSAID type, with loxoprofen (aHR = 3.95 [95% CI, 1.56\u201310.00]), celecoxib (aHR = 2.44 [95% CI, 1.68\u20133.53]), and naproxen (aHR = 4.7 [95% CI, 2.16\u201310.24]) showing statistically comparable risks, all of which were significantly higher than that of meloxicam (aHR = 1.22 [95% CI, 0.68\u20132.19]).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings enhance the understanding of NSAID safety profiles by identifying dose\u2013response and duration\u2013time AEs. They also contribute to better diagnosis and management of AEs while providing valuable guidelines for both patients and clinicians.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1539328","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T12:58:55Z","timestamp":1743598735000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Overall compilation of adverse effects of non-steroidal anti-inflammatory drugs: a hypothesis-free systematic investigation using a nationwide cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"Hyein","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Du Hyun","family":"Ro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyuk-Soo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungho","family":"Won","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"eadg6194","DOI":"10.1126\/sciadv.adg6194","article-title":"Possible link between statin and iron deficiency anemia: a South Korean nationwide population-based cohort study","volume":"9","author":"Ahn","year":"2023","journal-title":"Sci. Adv."},{"key":"B2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/pds.1077","article-title":"The withdrawal of rofecoxib","volume":"14","author":"Arellano","year":"2005","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B3","doi-asserted-by":"publisher","first-page":"j1909","DOI":"10.1136\/bmj.j1909","article-title":"Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data","volume":"357","author":"Bally","year":"2017","journal-title":"bmj"},{"key":"B4","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","article-title":"Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials","volume":"382","author":"Bhala","year":"2013","journal-title":"Lancet London, Engl."},{"key":"B5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1258\/jrsm.99.3.132","article-title":"Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis","volume":"99","author":"Caldwell","year":"2006","journal-title":"J. R. Soc. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.2165\/11633470-000000000-00000","article-title":"Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project)","volume":"35","author":"Castellsague","year":"2012","journal-title":"Drug Saf."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1016\/S0140-6736(17)30981-9","article-title":"Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial","volume":"389","author":"Chan","year":"2017","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e0261239","DOI":"10.1371\/journal.pone.0261239","article-title":"Cardiovascular safety of celecoxib in rheumatoid arthritis and osteoarthritis patients: a systematic review and meta-analysis","volume":"16","author":"Cheng","year":"2021","journal-title":"PloS one"},{"key":"B9","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1136\/bmj.325.7365.619","article-title":"Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials","volume":"325","author":"Deeks","year":"2002","journal-title":"Bmj"},{"key":"B10","first-page":"437","article-title":"Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen","volume":"62","author":"De Vecchis","year":"2014","journal-title":"Minerva Cardioangiol."},{"key":"B11","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.329.7471.867","volume-title":"Lessons from the withdrawal of rofecoxib","author":"Dieppe","year":"2004"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1096\/fasebj.12.12.1063","article-title":"Cyclooxygenase in biology and disease","volume":"12","author":"Dubois","year":"1998","journal-title":"FASEB J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1517\/14740338.2013.780595","article-title":"Safety of celecoxib compared with placebo and non-selective NSAIDs: cumulative meta-analysis of 89 randomized controlled trials","volume":"12","author":"Essex","year":"2013","journal-title":"Expert Opin. drug Saf."},{"key":"B14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1161\/CIRCULATIONAHA.116.026324","article-title":"Imprecision: limitations to interpretation of a large randomized clinical trial","volume":"135","author":"FitzGerald","year":"2017","journal-title":"Circulation"},{"key":"B15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1172\/JCI27291","article-title":"Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities","volume":"116","author":"Grosser","year":"2006","journal-title":"J. Clin. investigation"},{"key":"B16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/jcpt.12484","article-title":"Non\u2010steroidal anti\u2010inflammatory drug\u2010induced cardiovascular adverse events: a meta\u2010analysis","volume":"42","author":"Gunter","year":"2017","journal-title":"J. Clin. Pharm. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1007\/s00535-012-0717-6","article-title":"Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis","volume":"48","author":"Jarupongprapa","year":"2013","journal-title":"J. gastroenterology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"678","DOI":"10.4055\/cios22240","article-title":"Development of prediction model using machine-learning algorithms for nonsteroidal anti-inflammatory drug-induced gastric ulcer in osteoarthritis patients: retrospective cohort study of a nationwide South Korean cohort","volume":"15","author":"Jeong","year":"2023","journal-title":"Clin. Orthop. Surg."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","article-title":"Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials","volume":"332","author":"Kearney","year":"2006","journal-title":"Bmj"},{"key":"B20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.12997\/jla.2022.11.2.103","article-title":"Understanding and utilizing claim data from the Korean national health insurance service (NHIS) and health insurance review & assessment (HIRA) database for research","volume":"11","author":"Kyoung","year":"2022","journal-title":"J. Lipid Atheroscler."},{"key":"B21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.4078\/jrd.2016.23.1.47","article-title":"Gastrointestinal risk factors and non-steroidal anti-inflammatory drugs use in rheumatoid arthritis and osteoarthritis patients in Korea","volume":"23","author":"Lee","year":"2016","journal-title":"J. Rheumatic Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1093\/ije\/dyv319","article-title":"Cohort profile: the national health insurance service\u2013national sample cohort (NHIS-NSC), South Korea","volume":"46","author":"Lee","year":"2017","journal-title":"Int. J. Epidemiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1590\/2175-8239-JBN-2018-0107","article-title":"Pathophysiological aspects of nephropathy caused by non-steroidal anti-inflammatory drugs","volume":"41","author":"Lucas","year":"2018","journal-title":"Braz. J. Nephrol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1093\/eurheartj\/ehw387","article-title":"Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT)","volume":"38","author":"MacDonald","year":"2017","journal-title":"Eur. heart J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jcph.1302","article-title":"Cardiovascular risk of nonsteroidal anti\u2010inflammatory drugs and classical and selective cyclooxygenase\u20102 inhibitors: a meta\u2010analysis of observational studies","volume":"59","author":"Mart\u00edn Arias","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e1001098","DOI":"10.1371\/journal.pmed.1001098","article-title":"Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies","volume":"8","author":"McGettigan","year":"2011","journal-title":"PLoS Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.2147\/TCRM.S79135","article-title":"Adverse drug reactions and drug\u2013drug interactions with over-the-counter NSAIDs","volume":"11","author":"Moore","year":"2015","journal-title":"Ther. Clin. risk Manag."},{"key":"B28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.22265\/acnef.4.1.263","article-title":"Cyclooxygenase biology in renal function-literature review","volume":"4","author":"Moro","year":"2017","journal-title":"Rev. Colomb. Nefrol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1001\/jama.286.8.954","article-title":"Risk of cardiovascular events associated with selective COX-2 inhibitors","volume":"286","author":"Mukherjee","year":"2001","journal-title":"Jama"},{"key":"B30","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/s0014-5793(99)01088-1","article-title":"Immunolocalization of cyclooxygenase\u20102 in the macula densa of human elderly","volume":"457","author":"Nantel","year":"1999","journal-title":"FEBS Lett."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","article-title":"Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis","volume":"375","author":"Nissen","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/ehjcvp\/pvac015","article-title":"Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial","volume":"8","author":"Obeid","year":"2022","journal-title":"Eur. Heart Journal-Cardiovascular Pharmacother."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e002624","DOI":"10.1136\/bmjopen-2013-002624","article-title":"The relationship between osteoarthritis and cardiovascular disease in a population health survey: a cross-sectional study","volume":"3","author":"Rahman","year":"2013","journal-title":"BMJ open"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1007\/s00167-018-5333-4","article-title":"The use of bisphosphonates after joint arthroplasty is associated with lower implant revision rate","volume":"27","author":"Ro","year":"2019","journal-title":"Knee Surg. Sports Traumatol. Arthrosc."},{"key":"B35","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/s0889-8553(05)70247-8","article-title":"NSAIDs, gastrointestinal injury, and cytoprotection","volume":"25","author":"Scheiman","year":"1996","journal-title":"Gastroenterol. Clin."},{"key":"B36","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41569-020-0366-z","article-title":"Cardiovascular effects and safety of (non-aspirin) NSAIDs","volume":"17","author":"Schjerning","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1093\/aje\/kwj331","article-title":"Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case-control analysis","volume":"164","author":"Schneider","year":"2006","journal-title":"Am. J. Epidemiol."},{"key":"B38","first-page":"103","article-title":"Anxiety and depression in patients with osteoarthritis: impact and management challenges","volume-title":"Open access rheumatology: research and reviews","author":"Sharma","year":"2016"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study","volume":"284","author":"Silverstein","year":"2000","journal-title":"Jama"},{"key":"B40","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.amjmed.2005.09.054","article-title":"Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study","volume":"119","author":"Singh","year":"2006","journal-title":"Am. J. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev.biochem.69.1.145","article-title":"Cyclooxygenases: structural, cellular, and molecular biology","volume":"69","author":"Smith","year":"2000","journal-title":"Annu. Rev. Biochem."},{"key":"B42","doi-asserted-by":"publisher","first-page":"c7086","DOI":"10.1136\/bmj.c7086","article-title":"Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis","volume":"342","author":"Trelle","year":"2011","journal-title":"Bmj"},{"key":"B43","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ejim.2015.03.008","article-title":"Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: a systematic review and meta-analysis of observational studies","volume":"26","author":"Ungprasert","year":"2015","journal-title":"Eur. J. Intern. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/pds.3437","article-title":"Myocardial infarction and individual nonsteroidal anti\u2010inflammatory drugs meta\u2010analysis of observational studies","volume":"22","author":"Varas\u2010Lorenzo","year":"2013","journal-title":"Pharmacoepidemiol. drug Saf."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1053\/gast.1997.v112.pm9041264","article-title":"Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years","volume":"112","author":"Wallace","year":"1997","journal-title":"Gastroenterology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.21037\/atm-22-6181","article-title":"Comparison of cardiorenal safety of nonsteroidal anti-inflammatory drugs in the treatment of arthritis: a network meta-analysis","volume":"10","author":"Wang","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.joca.2007.12.013","article-title":"OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines","volume":"16","author":"Zhang","year":"2008","journal-title":"Osteoarthr. Cartil."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1539328\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T12:59:07Z","timestamp":1743598747000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1539328\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":47,"alternative-id":["10.3389\/fphar.2025.1539328"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1539328","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"article-number":"1539328"}}